Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Endometrioid | 6 | 2023 | 271 | 1.610 |
Why?
|
| Endometrial Neoplasms | 8 | 2023 | 1351 | 1.510 |
Why?
|
| Genital Neoplasms, Female | 9 | 2023 | 516 | 1.220 |
Why?
|
| Ovarian Neoplasms | 15 | 2023 | 4823 | 1.100 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2023 | 59 | 0.910 |
Why?
|
| Anal Canal | 3 | 2018 | 376 | 0.740 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2023 | 450 | 0.740 |
Why?
|
| Carcinosarcoma | 2 | 2017 | 108 | 0.690 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2017 | 221 | 0.680 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2017 | 484 | 0.660 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2023 | 3471 | 0.660 |
Why?
|
| Anus Neoplasms | 3 | 2018 | 332 | 0.610 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 663 | 0.590 |
Why?
|
| Vulvar Neoplasms | 3 | 2022 | 272 | 0.520 |
Why?
|
| Papillomaviridae | 3 | 2018 | 1118 | 0.510 |
Why?
|
| Laparotomy | 1 | 2017 | 474 | 0.490 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2018 | 385 | 0.480 |
Why?
|
| Cervix Uteri | 1 | 2018 | 591 | 0.480 |
Why?
|
| Neoplasm Staging | 16 | 2023 | 11001 | 0.460 |
Why?
|
| Hysterectomy | 2 | 2021 | 927 | 0.410 |
Why?
|
| Endometrium | 1 | 2014 | 424 | 0.400 |
Why?
|
| Papillomavirus Infections | 3 | 2018 | 1585 | 0.390 |
Why?
|
| Healthcare Disparities | 4 | 2023 | 3151 | 0.380 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2018 | 2011 | 0.330 |
Why?
|
| Databases, Factual | 7 | 2017 | 7716 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 2721 | 0.280 |
Why?
|
| Lymph Node Excision | 7 | 2023 | 1248 | 0.280 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2017 | 199 | 0.240 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2022 | 701 | 0.180 |
Why?
|
| Lymph Nodes | 3 | 2022 | 3465 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 5522 | 0.170 |
Why?
|
| Female | 36 | 2023 | 379592 | 0.160 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2022 | 336 | 0.160 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2021 | 357 | 0.160 |
Why?
|
| Aged, 80 and over | 14 | 2023 | 57683 | 0.160 |
Why?
|
| Rhode Island | 1 | 2018 | 347 | 0.150 |
Why?
|
| Gynecology | 1 | 2022 | 509 | 0.150 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 974 | 0.140 |
Why?
|
| Aged | 20 | 2023 | 162944 | 0.140 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2017 | 84 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 6534 | 0.140 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 299 | 0.140 |
Why?
|
| Middle Aged | 22 | 2023 | 213127 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2019 | 1905 | 0.130 |
Why?
|
| Survival Rate | 4 | 2017 | 12773 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13655 | 0.130 |
Why?
|
| Ovariectomy | 1 | 2017 | 660 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 424 | 0.120 |
Why?
|
| Genital Diseases, Female | 1 | 2016 | 197 | 0.120 |
Why?
|
| Germ-Line Mutation | 2 | 2023 | 1786 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2021 | 971 | 0.120 |
Why?
|
| Education | 1 | 2017 | 543 | 0.120 |
Why?
|
| Microsatellite Instability | 1 | 2017 | 678 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2723 | 0.110 |
Why?
|
| Retrospective Studies | 10 | 2023 | 77098 | 0.110 |
Why?
|
| Social Support | 1 | 2023 | 2117 | 0.110 |
Why?
|
| Humans | 36 | 2023 | 742088 | 0.110 |
Why?
|
| Robotics | 1 | 2020 | 892 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 12344 | 0.110 |
Why?
|
| Fertility | 1 | 2017 | 770 | 0.110 |
Why?
|
| Psychometrics | 1 | 2021 | 2999 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2022 | 40450 | 0.100 |
Why?
|
| Genetic Counseling | 1 | 2015 | 600 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 1145 | 0.100 |
Why?
|
| United States | 9 | 2023 | 69693 | 0.090 |
Why?
|
| Adult | 18 | 2023 | 213712 | 0.090 |
Why?
|
| Cause of Death | 2 | 2017 | 3571 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3612 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2016 | 2266 | 0.080 |
Why?
|
| Social Class | 1 | 2017 | 1995 | 0.080 |
Why?
|
| Insurance, Health | 2 | 2017 | 2493 | 0.070 |
Why?
|
| Anxiety | 1 | 2021 | 4279 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 4029 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1659 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2023 | 53187 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2014 | 1057 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2938 | 0.070 |
Why?
|
| Risk | 1 | 2018 | 9679 | 0.070 |
Why?
|
| Comorbidity | 2 | 2017 | 10372 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2017 | 1895 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 2107 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2016 | 2121 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2038 | 0.060 |
Why?
|
| Infant Behavior | 1 | 2005 | 156 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2017 | 3679 | 0.060 |
Why?
|
| Young Adult | 6 | 2023 | 56350 | 0.060 |
Why?
|
| Genotype | 1 | 2018 | 12946 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 11363 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15056 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2015 | 3439 | 0.050 |
Why?
|
| Quality of Life | 4 | 2023 | 12730 | 0.050 |
Why?
|
| Endometrial Hyperplasia | 1 | 2021 | 96 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2020 | 5774 | 0.050 |
Why?
|
| Propensity Score | 2 | 2017 | 1771 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2005 | 580 | 0.040 |
Why?
|
| Pelvis | 1 | 2023 | 730 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 7901 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2020 | 62966 | 0.040 |
Why?
|
| Reproduction | 1 | 2022 | 668 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 379 | 0.040 |
Why?
|
| Logistic Models | 3 | 2017 | 13403 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20086 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 802 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39004 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2022 | 2906 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 401 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 505 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1507 | 0.030 |
Why?
|
| Animals | 2 | 2015 | 168561 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2005 | 2407 | 0.030 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2015 | 324 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 2384 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 1066 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 1533 | 0.030 |
Why?
|
| Motivation | 1 | 2020 | 1968 | 0.020 |
Why?
|
| Registries | 2 | 2017 | 8077 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2016 | 852 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2018 | 2739 | 0.020 |
Why?
|
| Age Factors | 2 | 2017 | 18355 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2015 | 2224 | 0.020 |
Why?
|
| Massachusetts | 1 | 2021 | 8662 | 0.020 |
Why?
|
| Income | 1 | 2017 | 1904 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 20774 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 24913 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2016 | 2049 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2018 | 2235 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 29010 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 1513 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2020 | 4681 | 0.020 |
Why?
|
| Critical Care | 1 | 2017 | 2640 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 10248 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 9846 | 0.010 |
Why?
|
| Medicaid | 1 | 2016 | 2716 | 0.010 |
Why?
|
| Hospitals | 1 | 2016 | 3937 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 9185 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2015 | 3527 | 0.010 |
Why?
|
| Syndrome | 1 | 2005 | 3248 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 6347 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 21719 | 0.010 |
Why?
|
| Gestational Age | 1 | 2005 | 3490 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 2795 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17400 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 72145 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 85649 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2005 | 25575 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2005 | 23320 | 0.000 |
Why?
|
| Pregnancy | 1 | 2005 | 29087 | 0.000 |
Why?
|
Concepts
(147)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(37)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_